TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 5.5nMAssay Description:Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 6.10nMAssay Description:Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 7.30nMAssay Description:Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 7.90nMAssay Description:Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8.10nMAssay Description:Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 19nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 28nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 100nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 240nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 250nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 260nMAssay Description:Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 830nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
Ono Pharmaceutical
Curated by ChEMBL
Ono Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 5.40E+3nMAssay Description:Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrsMore data for this Ligand-Target Pair